drugset / Trial / NCT04343261

Convalescent Plasma in the Treatment of COVID 19

NCT04343261

Phase 2 Completed 48 enrolled Trinity Health Of New England
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to collect blood from previously COVID-19 infected persons who have recovered and use it as a treatment for those who are currently sick with a severe or life-threatening COVID-19 infection.

Timeline

Start
2020-04-10
Primary completion
2020-07-23
Completion
2020-08-13

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Convalescent Plasma Protein / enzyme biologic 2 unknown Other

Indications